One-Year Follow-Up Result of TARGET I Clinical Endpoint Appraisal Committee Conference Held in Beijing
Shanghai, June 25, 2012--MicroPort Scientific Corporation announced that the primary endpoint results from prospective, multicenter, randomized clinical trials for assessing the safety and effacy of Firehawk has be evaluated in the committee conference held in Beijing. Committee president, Professor Yong Huo, and other two committee members, Professor Weimin Wang and Professor Gao Wei, were invited. After analyzing data of endpoint results, including Major Adverse Cardiac Events (MACE) and related angiographic results, three professors made a rigorous, independent and authoritative appraisement and discussion, and the result will be submitted to related committee department for further data processing and analysis.
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.